BR112018012055A2 - substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico - Google Patents

substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico

Info

Publication number
BR112018012055A2
BR112018012055A2 BR112018012055A BR112018012055A BR112018012055A2 BR 112018012055 A2 BR112018012055 A2 BR 112018012055A2 BR 112018012055 A BR112018012055 A BR 112018012055A BR 112018012055 A BR112018012055 A BR 112018012055A BR 112018012055 A2 BR112018012055 A2 BR 112018012055A2
Authority
BR
Brazil
Prior art keywords
substrate
diagnostic
labeling
interest
pharmaceutical
Prior art date
Application number
BR112018012055A
Other languages
English (en)
Inventor
Schraeml Michael
Steffen Wojtek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112018012055A2 publication Critical patent/BR112018012055A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Abstract

a presente invenção diz respeito a um substrato de transglutaminase (tg) recombinante compreendendo uma sequência de aminoácidos do domínio fkbp de um polipeptídeo fkbp, em que o domínio ?insert-in-flap? (if) deste polipeptídeo é pelo menos em parte substituído por uma sequência de aminoácidos (?q-tag?) de 5 a 20 aminoácidos compreendendo uma sequência que possui pelo menos 80% de identidade de sequência com a porção yryrq da sequência peptídica x1-yryrq-x2 (seq id no: 1), e em que o referido substrato de tg é um substrato para a função tg da tg de kutzneria albida (kalbtg). além disso, a presente invenção diz respeito aos usos do referido substrato.
BR112018012055A 2015-12-15 2016-12-13 substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico BR112018012055A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200111 2015-12-15
PCT/EP2016/080847 WO2017102759A1 (en) 2015-12-15 2016-12-13 Fkbp domain with transglutaminase recognition site

Publications (1)

Publication Number Publication Date
BR112018012055A2 true BR112018012055A2 (pt) 2018-12-04

Family

ID=55068769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012055A BR112018012055A2 (pt) 2015-12-15 2016-12-13 substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico

Country Status (8)

Country Link
US (1) US20190381181A1 (pt)
EP (1) EP3390424B1 (pt)
JP (1) JP6967002B2 (pt)
KR (1) KR20180087431A (pt)
CN (1) CN108699104B (pt)
BR (1) BR112018012055A2 (pt)
ES (1) ES2896100T3 (pt)
WO (1) WO2017102759A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022045151A1 (ja) * 2020-08-24 2022-03-03 天野エンザイム株式会社 改変タンパク質の製造方法
EP4201956A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Kutzneria albida (kalbtg) transglutaminase used for antibody conjugations
EP4201430A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Modified antibody for site-specific conjugation and its diagnostic use
WO2024017923A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Linkers for site-specific antibody conjugation
CN117551678A (zh) * 2023-12-29 2024-02-13 山东理工大学 一种提高丙酮酸脱羧酶SsPDC在大肠杆菌中可溶性表达的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1151299A4 (en) * 1999-01-22 2003-06-04 Smithkline Beecham Corp PROCESS OF LOCATION-SPECIFIC MARKING OF PROTEINS AND APPLICATIONS
US7244819B2 (en) * 2001-06-22 2007-07-17 Roche Diagnostics Operations, Inc. Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides
EP1971684B1 (en) * 2006-01-03 2011-10-05 Roche Diagnostics GmbH Chimaeric fusion protein with superior chaperone and folding activities
EP2222694B1 (en) * 2007-12-13 2014-01-15 Roche Diagnostics GmbH Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
EP2635310A2 (en) * 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
EP2841090A1 (en) * 2012-04-24 2015-03-04 Amylin Pharmaceuticals, LLC Site-specific enzymatic modification of exendins and analogs thereof
ES2603589T3 (es) * 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
CN103421753B (zh) * 2013-07-25 2015-02-11 江南大学 一种酶活和热稳定性提高的谷氨酰胺转胺酶突变体及其构建方法
JP6757319B2 (ja) * 2014-12-19 2020-09-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 微生物トランスグルタミナーゼ、その基質、およびその使用方法

Also Published As

Publication number Publication date
WO2017102759A1 (en) 2017-06-22
EP3390424B1 (en) 2021-09-01
US20190381181A1 (en) 2019-12-19
JP6967002B2 (ja) 2021-11-17
CN108699104B (zh) 2022-07-15
CN108699104A (zh) 2018-10-23
EP3390424A1 (en) 2018-10-24
ES2896100T3 (es) 2022-02-23
JP2019508366A (ja) 2019-03-28
KR20180087431A (ko) 2018-08-01

Similar Documents

Publication Publication Date Title
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
CL2021000519A1 (es) (divisional de solicitud 732-2018) anticuerpo anti-vegf y su uso en el tratamiento de la angiogénesis patológica.
BR112017022298A2 (pt) geranilgeranil pirofosfato sintase
BR112017019625A2 (pt) udp-glicosiltransferases
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
BR122020006914B8 (pt) Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112018010805A2 (pt) mutantes de proteína f de rsv
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112017020308A2 (pt) udp-glicosiltransferases
BR112018008681A2 (pt) novos polipeptídeos com estabilidade proteolítica melhorada, e métodos para preparar e usar os mesmos
BR112017011398A2 (pt) métodos e composições que usam polipeptídeos variantes de klotho
BR112014030440A8 (pt) método para preparar um alqueno monoinsaturado
BR112015017797A2 (pt) celobio-hidrolase termoestável
BR112013013548B8 (pt) Proteína de fusão anticancerígena
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112014024751A2 (pt) antígenos de clostridium difficile
BR112016020492A2 (pt) fibronectina estabilizada com base nas estruturas de moléculas
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112017026142A2 (pt) composições e métodos para tratar doença sprue celíaca

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.